Jin Zhaohui, Yoon Harry H
Department of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Department of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Hematol Oncol Clin North Am. 2017 Jun;31(3):499-510. doi: 10.1016/j.hoc.2017.01.008. Epub 2017 Mar 22.
Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti-human epidermal growth factor receptor 2 therapy.
抗血管生成疗法是仅有的两种经证实可提高晚期胃腺癌或胃食管交界（GEJ）腺癌总体生存率超过标准治疗的生物靶向治疗方法之一。靶向血管内皮生长因子受体2可提高先前接受治疗的晚期胃/GEJ腺癌患者的总体生存率。尚无抗血管生成疗法在初治或可切除的食管胃癌患者或肿瘤起源于食管的患者中显示出总体生存获益。正在进行的有前景的临床研究包括抗血管生成疗法与免疫检查点抑制及抗人表皮生长因子受体2疗法的联合应用。
